Endothelial-targeted gene transfer of hypoxia-inducible factor-1α augments ischemic neovascularization following systemic administration

Molecular Therapy

Volumn 16, Issue 12, 2008, Pages 1927-1936

  Tal, Reshef ^a,b,c   Shaish, Aviv ^a,b   Rofe, Karen ^b   Feige, Erez ^a   Varda Bloom, Nira ^a,b   Afek, Arnon ^b   Barshack, Iris ^a,b   Bangio, Livnat ^a   Hodish, Israel ^a,b   Greenberger, Shoshana ^a,b   Peled, Michael ^a,b   Breitbart, Eyal ^a   Harats, Dror ^a,b  

^a Vascular Biogenics Ltd   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PREPROENDOTHELIN 1;

ANGIOGENIC GENE THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; MUSCLE ISCHEMIA; MUSCLE PERFUSION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN DOMAIN; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ENDOTHELIUM; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISCHEMIA; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SUBSTRATE SPECIFICITY; TRANSGENES;

ADENOVIRIDAE; CYTOMEGALOVIRUS; MURINAE; MUS;

EID: 56749096616     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.191     Document Type: Article

References (48)

1. Losordo, DW and Dimmeler, S (2004). Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: Angiogenic cytokines. Circulation 109: 2487-2491.
2. Kastrup, I, Jørgensen, E, Rück, A, Tägil, K, Glogar, D, Ruzyllo, W et al. (2005). Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: The Euroinject One trial. J Am Coll Cordiol 45: 982-988.
3. Rajagopalan, S, Mohler, E 3rd, Lederman, RJ, Saucedo, J, Mendelsohn, FO, Olin, J et al. (2003). Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: Design of the RAVE triall. Am Heart J 145: 1114-1118.
4. Bruick, RK and McKnight, SL (2001). A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340.
5. Masson, N, Willam, C, Maxwell, PH, Pugh, CW and Ratcliffe, PJ (2001). Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 20: 5197-5206.
6. Lando, D, Peet, DJ, Whelan, DA, Gorman, JJ and Whitelaw, ML (2002). Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295: 858-861.
7. Shyu, KG, Wang, MT, Wang, BW, Chang, CC, Leu, JG, Kuan, P et al. (2002). Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an cute myocardial infarction model in the rat. Cardiovasc Res 54: 576-583.
8. Vincent, KA, Shyu, KG, Luo, Y, Magner, M, Tio, RA, Jiang, C et al. (2000). Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 102: 2255-2261.
9. Patel, TH, Kimura, H, Weiss, CR, Semenza, GL and Hofmann, LV (2005). Constitutively active HIF-1alpha improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc Res 68: 144-154.
10. Pajusola, K, Kunnapuu, J, Vuorikoski, S, Soronen, J, André, H, Pereira, T et al. (2005). Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. FASEB J 19: 1365-1367.
11. Rajagopalan, S, Olin, J, Deitcher, S, Pieczek, A, Laird, J, Grossman, PM et al. (2007). Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: Phase I dose-escalation experience. Circulation 115: 1234-1243.
12. Baek, JH, Mahon, PC, Oh, J, Kelly, B, Krishnamachary, B, Pearson, M et al. (2005). OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol Cell 17: 503-512.
13. Tal, R, Shaish, A, Bangio, L, Peled, M, Breitbart, E and Harats, D (2008). Activation of C-transactivation domain is essential for optimal HIF-1alpha-mediated transcriptional and angiogenic effects. Microvasc Res 76: 1-6.
14. Yla-Herttuala, S and Alitalo, K (2003). Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 9: 694-701.
15. Wood, M, Perrotte, P, Onishi, E, Harper, ME, Dinney, C, Pagliaro, L et al. (1999). Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther 6: 367-372.
16. Thurston, G, Rudge, JS, Ioffe, E, Zhou, H, Ross, L, Croll, SD et al. (2000). Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6: 460-463.
17. Harats, D, Kurihara, H, Belloni, P, Oakley, H, Ziober, A, Ackley, D et al. (1995). Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J Clin Invest 95: 1335-1344.
18. Varda-Bloom, N, Shaish, A, Gonen, A, Levanon, K, Greenbereger, S, Ferber, S et al. (2001). Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther 8: 819-827.
19. Jäger, U, Zhao, Y and Porter, CD (1999). Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences. J Virol 73: 9702-9709.
20. Greenberger, S, Shaish, A, Varda-Bloom, N, Levanon, K, Breitbart, E, Goldberg, I et al. (2004). Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest 113: 1017-1024.
21. Peled, M, Shaish, A, Greenberger, S, Katav, A, Hodish, I, Ben-Shushan, D et al. (2008). Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect. Cancer Gene Ther 15: 535-542.
22. Levanon, K, Varda-Bloom, N, Greenberger, S, Barshack, I, Goldberg, I, Orenstein, A et al. (2006). Vascular wall maturation and prolonged angiogenic effect by endothelial-specific platelet-derived growth factor expression. Pathobiology 73: 149-158.
23. Reynolds, PN, Nicklin, SA, Kaliberova, L, Boatman, BG, Grizzle, WE, Balyasnikova, IV et al. (2001). Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 19: 838-842.
24. Nicklin, SA, Reynolds, PN, Brosnan, MJ, White, SJ, Curiel, DT, Dominiczak, AF et al. (2001). Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension 38: 65-70.
25. Appleby, CE, Kingston, PA, David, A, Gerdes, CA, Umaã, P, Castro, MG et al. (2003). A novel combination of promoter and enhancers increases transgene expression in vascular smooth muscle cells in vitro and coronary arteries in vivo after adenovirus-mediated gene transfer. Gene Ther 10: 1616-1622.
26. Kim, S, Lin, H, Barr, E, Chu, L, Leiden, JM and Parmacek, MS (1997). Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. J Clin Invest 100 1006-1014.
27. Wickham, TJ, Segal, DM, Roelvink, PW, Carrion, ME, Lizonova, A, Lee, GM et al. (1996). Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 70: 6831-6838.
28. Reynolds, PN, Zinn, KR, Gavrilyuk, VD, Balyasnikova, IV, Rogers, BE, Buchsbaum, DJ et al. (2000). A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2: 562-578.
29. Nettelbeck, DM, Miller, DW, Jerome, V, Zuzarte, M, Watkins, SJ, Hawkins, RE et al. (2001). Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 3: 882-891.
30. Work, LM, Nicklin, SA, Brain, NJ, Dishart, KL, Von Seggern, DJ, Hallek, M et al. (2004). Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther 9: 198-208.
31. Bu, X and Quertermous, T (1997). Identification of an endothelial cell-specific regulatory region in the murine endothelin-1 gene. J Biol Chem 272: 32613-32622.
32. Mahasreshti, PJ, Kataram, M, Wang, MH, Stockard, CR, Grizzle, WE, Carey, D et al. (2003). Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 9: 2701-2710.
33. Phaneuf, D, Chen, SJ and Wilson, JM (2000). Intravenous injection of an adenovirus encoding hepatocyte growth factor results in liver growth and has a protective effect against apoptosis. Mol Med 6: 96-103.
34. Piret, JP, Mottet, D, Raes, M and Michiels, C (2002). CoCl2, a chemical inducer of hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2. Ann NY Acad Sci 973: 443-447.
35. Gwak, GY, Yoon, JH, Kim, KM, Lee, HS, Chung, JW and Gores, GJ (2005). Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 42: 358-364.
36. Carmeliet, P, Dor, Y, Herbert, JM, Fukumura, D, Brusselmans, K, Dewerchin, M et al. (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 3 485-490.
37. Helton, R, Cui, J, Scheel, JR, Ellison, JA, Ames, C, Gibson, C et al. (2005). Brain-specific knock-out of hypoxia-inducible factor-1alpha reduces rather than increases hypoxic-ischemic damage. J Neurosci 25: 4099-4107.
38. Couffinhal, T, Silver, M, Zheng, LP, Kearney, M, Witzenbichler, B and Isner, JM (1998). Mouse model of angiogenesis. Am J Path 152 1667-1679.
39. Couffinhal, T, Silver, M, Kearney, M, Sullivan, A, Witzenbichler, B, Magner, M et al. (1999). Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/-mice. Circulation 99: 3188-3198.
40. Ackah, E, Yu, J, Zoellner, S, Iwakiri, Y, Skurk, C, Shibata, R et al. (2005). Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest 115: 2119-2127.
41. Masaki, I, Yonemitsu, Y, Yamashita, A, Sata, S, Tanii, M, Komori, K et al. (2002). Angiogenic gene therapy for experimental critical limb ischemia: Acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 90: 966-973.
42. Hiasa, K, Ishibashi, M, Ohtani, K, Inoue, S, Zhao, Q, Kitamoto, S et al. (2004). Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: Next-generation chemokine therapy for therapeutic neovascularization. Circulation 109: 2454-2461.
43. Cao, R, Brakenhielm, E, Pawliuk, R, Wariaro, D, Post, MJ, Wahlberg, E et al. (2003). Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9: 604-613.
44. Rivard, A, Silver, M, Chen, D, Kearney, M, Magner, M, Annex, B et al. (1999). Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Path 154: 355-363.
45. Mack, CA, Magovern, CJ, Budenbender, KT, Patel, SR, Schwarz, EA, Zanzonico, P et al. (1998). Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg 27 699-709.
46. Naldini, A and Carraro, F (2005). Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy 4: 3-8.
47. Kelly, BD, Hackett, SF, Hirota, K, Oshima, Y, Cai, Z, Berg-Dixon, S et al. (2003). Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 93: 1074-1081.
48. Bosch-Marce, M, Okuyama, H, Wesley, JB, Sarkar, K, Kimura, H, Liu, YV et al. (2007). Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res 101: 1310-1318.